Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24709851 | 0.87 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL30223258 | 0.86 | TP53 (0.47) | ALDH1A1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL175092 | 0.86 | TP53 (0.47) | ALDH1A1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL14357208 | 0.85 | MAPK1 (0.65) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL18300851 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL18496413 | 0.83 | TP53 (0.45) | ALDH1A1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL29819597 | 0.82 | SLC16A3 (0.59) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL18302452 | 0.82 | SLC16A3 (0.59) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL6068367 | 0.81 | TP53 (0.43) | ALDH1A1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL6222697 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2025-08-14 | — | — | US | disclosed |
| US-12187682-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2024-03-28 | — | — | US | disclosed |
| US-11724989-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-20220251045-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| US-20190112274-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-10202350-B2 | MCT4 inhibitors for treating disease | Vettore, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2018111904-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
| EP-3307068-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016201426-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | Vettore, LLC (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-15 | — | — | US | disclosed |
| US-7135474-B2 | Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER HEALTHCARE AG (DE) | 2006-11-14 | — | — | US | disclosed |
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187682-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | ALDH1A1 811/4885MEN1 339/4885KMT2A 1965/4885 |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | ALDH1A1 665/4885MEN1 1465/4885KMT2A 3137/4885 |
| US-20250257039-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | ALDH1A1 811/4885MEN1 339/4885KMT2A 1965/4885 |
| US-10202350-B2 | MCT4 inhibitors for treating disease | SLC16A3, SLC16A1, MCTS1 | ALDH1A1 1021/4885MEN1 1340/4885KMT2A 3004/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | ALDH1A1 665/4885MEN1 1465/4885KMT2A 3137/4885 |
| US-20220251045-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | ALDH1A1 811/4885MEN1 339/4885KMT2A 1965/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | ALDH1A1 665/4885MEN1 1465/4885KMT2A 3137/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | ALDH1A1 665/4885MEN1 1465/4885KMT2A 3137/4885 |
| US-20190112274-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A7 | ALDH1A1 811/4885MEN1 339/4885KMT2A 1965/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | ALDH1A1 665/4885MEN1 1465/4885KMT2A 3137/4885 |
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | PDE3B, PDE5A, PDE3A | ALDH1A1 1157/4885MEN1 2117/4885KMT2A 3020/4885 |
| US-20240101518-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A1, SLC16A3, SLC16A8 | ALDH1A1 633/4885MEN1 287/4885KMT2A 2226/4885 |
| US-20160362378-A1 | MCT4 INHIBITORS FOR TREATING DISEASE | SLC16A3, SLC16A1, MCTS1 | ALDH1A1 1021/4885MEN1 1340/4885KMT2A 3004/4885 |
| US-11724989-B2 | MCT4 inhibitors for treating disease | SLC16A1, SLC16A3, SLC16A7 | ALDH1A1 811/4885MEN1 339/4885KMT2A 1965/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | ALDH1A1 559/4885MEN1 848/4885KMT2A 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.